BRIEF—Eleven Biotherapeutics changes name to Sesen Bio

USA-based oncology specialist Eleven Biotherapeutics has announced that the company is changing its name to Sesen Bio Inc.

Sesen Bio will trade under the new Nasdaq ticker symbol “SESN,” effective on May 17, 2018. The former ticker symbol “EBIO” will remain effective through the market close on May 16, 2018. The new website for Sesen Bio is www.sesenbio.com.

Additionally, the company announced the appointments of Dr Hagop Youssoufian as senior medical advisor and Dr Madhu Anant as vice president of regulatory affairs.

“Over the last several years, we have undergone an incredible transformation as a company, and our new name, Sesen Bio, reinforces this evolution and our focused commitment to oncology drug development. Sesen, an ancient symbol of the lotus flower, represents life and our mission to bring forward medicines that will improve and preserve the lives of those with devastating cancers,” said Stephen Hurly, president and chief executive of Sesen Bio.

“The additions of Dr Youssoufian and Dr Anant further strengthen our leadership team and drug development capabilities as we work to bring our lead asset, Vicinium, through Phase III development for high-grade non-muscle invasive bladder cancer and advance regulatory interactions. 2018 is set to be a significant year for Sesen Bio, as we are well on our way to achieving our vision and bettering the lives of people in need,” he added.